Ubs Oconnor LLC Astria Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.72 Billion
- Q2 2024
A detailed history of Ubs Oconnor LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 112,665 shares of ATXS stock, worth $1.26 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
112,665Holding current value
$1.26 Million% of portfolio
0.06%Shares
5 transactions
Others Institutions Holding ATXS
# of Institutions
102Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$72.8 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$56.6 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$40.5 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$39.9 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$39.5 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $170M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...